PER-056-06已完成未知
DOUBLE BLIND STUDY, RANDOMIZED, WITH PARALLEL GROUPS, MULTICENTER, MULTINATIONAL, COMPARATIVE, OF THE SAFETY AND EFFICACY OF CETROMYCIN 300 MG QD AND CLARITROMYCIN (BIAXIN FILMTAB) 250 MG BID FOR THE TREATMENT OF PNEUMONIA ACQUIRED IN THE COMMUNITY OF ADULTS.
ADVANCE LIFE SCIENCE, INC.,0 个研究点目标入组 0 人开始时间: 2006年9月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •1. Ambulatory subjects men or women over 18 years of age.
- •2. Women should not be breastfeeding or have any risk of pregnancy for one of the following reasons: a) Postmenopausal for at least 1 year, surgically sterile or b) if they are of childbearing age, the subject should have a Pregnancy analysis of human chorionic gonadotropin (HCG) negative and should be using a highly effective method of birth control during the course of the study.
- •3. The subject should have a chest radiograph that indicated a clinical diagnosis of bacterial pneumonia according to the interpretation of the radiologist.
- •4. The subject should be a suitable candidate for oral antibiotic therapy and should be able to swallow the capsules intact.
- •5. The subject must present a recent respiratory disease that, based on the consideration of the signs and symptoms after the physical examination, is consistent with the diagnosis of bacterial CAP.
- •6. It is necessary that samples of the subjects are collected for microbiological documentation within 48 hours prior to enrollment.
- •7. Voluntary informed consent must be obtained in writing by the subject (or his / her legal representative) before the beginning of any procedure related to the study.
排除标准
- •1. A previous hospitalization within the previous 4 weeks or residency in a chronic care unit.
- •2. Evidence of active tuberculosis, empyema, lung abscess, pulmonary embolism, pulmonary edema, cystic fibrosis, tumor that compromises the lung, bronchial obstruction, history of postobstructive pneumonia or pneumonia Pneumocystis carinii known or suspected of the same.
- •3. Treatment with a long-acting injectable antimicrobial agent within 4 weeks, treatment with antibiotics such as ceftriaxone, azithromycin or dirithromycin within 7 days, or subjects who have received more than 24 hours of treatment with other antibiotics within 7 days prior to the administration of the study medication.
- •4 weeks, treatment with antibiotics such as ceftriaxone, azithromycin or dirithromycin within 7 days, or subjects who have received more than 24 hours of treatment with other antibiotics within 7 days. days prior to the administration of the study medication.
- •4. Any infection that requires the use of a concomitant antimicrobial agent in addition to the study medication.
- •5. History of hypersensitivity or allergic reactions to antimicrobial agents macrolides, ketolides, quinolones, azolides or streptogramins.
- •6. Treatment with a research medication within 4 weeks prior to the administration of the study medication.
- •7. Subjects women who are pregnant or breastfeeding.
- •8. Subjects with significant known liver or kidney deterioration (or disease).
- •9. Subjects with a history of renal dysfunction.
- •10. Evidence of cardiovascular, pulmonary, metabolic, gastrointestinal, neurological or endocrine disease, malignancy or other abnormality of uncontrolled clinical importance.
- •11. Subjects who would need parenteral antimicrobial therapy for the treatment of pneumonia should not enroll in the study.
- •12. Any underlying morbid condition or picture that could interfere with the implementation of study procedures and evaluations or the absorption of study medication.
- •13. Currently, they receive or are likely to receive any of the following medications: Astemizole (Hismanal®) or Pimozide (Orap®).
- •14. At present, they are receiving or are likely to receive any of the following medications: a) Theophylline or any theophylline analog. b) carbamazepine, dexamethasone, phenobarbital, phenytoin, hypericum, lamotrigine, troglitazone, warfarin and digitalis glycoside. c) Midazolam, triazolam and alprazolam. d) Simvastatin, lovastatin and atorvastatin.
- •15. Subject who is currently receiving or likely to need any of the following medications: a) Other systemic antibiotic therapy. b) Rifampin or rifabutin.
- •16. Immunocompromised subjects.
- •17. Subjects with knowledge or suspicion of a CNS disorder that may predispose the subject to suffer seizures or lower the seizure threshold.
- •18. Previous treatment in this study or another study of cetromycin.
- •19. Subjects with signs of septic shock.
研究者
相似试验
已完成
不适用
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)-D693 Idiopathic thrombocytopenic purpuraD693Idiopathic thrombocytopenic purpuraPER-041-05GLAXOSMITHKLINE PERU S.A.,
已完成
不适用
DOUBLE BLIND STUDY PARALLEL RANDOMIZED AND ACTIVE COMPARATOR WHOSE PURPOSE IS TO EVALUATE THE SAFETY AND EFFICACY OF CELECOXIB IN SUSPENSION COMPARED WITH NAPROXEN IN SUSPENSION IN PATIENTS WITH YOUNG RHEUMATOID ARTHRITIS.PER-049-02PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, INDUCED UNDER INTERNAL BLIND CONDITIONS, TO DETERMINE THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF THE APREPITANT REGIME COMPARED TO AN ONDASETRON REGIME FOR THE PREVENTION OF NAUSEA AND VOMITES INDUCED BY CHEMOTHERAPY, ASSOCIATED WITH HIGH DOSE OF CISPLATINO IN CYCLE 1.PER-057-03MERCK & CO.INC.,
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY ASSESSING THE EFFICACY AND SAFETY OF SARILUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN PATIENTS WITH RHEUMATOID.PER-081-14Sanofi Aventis Recherche & Development,18
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF 52 WEEKS OF ONCE DAILY TREATMENT OF ORALLY INHALED TIOTROPIUM + OLODATEROL FIXED DOSE COMBINATION (2.5 µG / 5 µG; 5 µG / 5 µG) (DELIVERED BY THE RESPIMAT) COMPARED…PER-089-11Boehringer Ingelheim,